Literature DB >> 9560017

Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study.

P Giannakopoulos1, E Kövari, L E French, I Viard, P R Hof, C Bouras.   

Abstract

Clusterin is a secreted glycoprotein that is expressed in response to tissue injury both in peripheral organs and in the brain. Recent studies have shown a substantial increase in clusterin mRNA in pyramidal neurons of the hippocampus and the entorhinal cortex in Alzheimer's disease (AD), with clusterin immunoreactivity occurring in neuropil threads, neurofibrillary tangles (NFT), and senile plaques. To elucidate further the role of this protein in the degenerative process, a quantitative study of its distribution in the cerebral cortex of non-demented and AD patients, all older than 85 years of age, was performed using immunocytochemistry. Using a stereological approach, we found that in cortical areas affected in AD, such as the entorhinal, inferior temporal and superior frontal cortices, the percentage of NFT-free neurons displaying clusterin immunoreactivity was significantly higher than that in non-demented cases. No such increase in the density of clusterin-immunoreactive neurons was seen in cortical areas that were less affected in the disease process. Furthermore, clusterin immunoreactivity was rarely observed in NFT-containing neurons. In conjunction with previous observations in peripheral tissues, these data suggest that clusterin may have a neuroprotective role, and that in AD, low cellular expression of this protein may be associated with neuronal degeneration and death.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560017     DOI: 10.1007/s004010050815

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  24 in total

1.  Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

Authors:  Jose Morales-Corraliza; Stephen D Schmidt; Matthew J Mazzella; Jason D Berger; Donald A Wilson; Daniel W Wesson; Mathias Jucker; Efrat Levy; Ralph A Nixon; Paul M Mathews
Journal:  Neurobiol Aging       Date:  2012-05-18       Impact factor: 4.673

Review 2.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

3.  Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.

Authors:  Madhav Thambisetty; Yang An; Anna Kinsey; Deepthi Koka; Muzamil Saleem; Andreas Güntert; Michael Kraut; Luigi Ferrucci; Christos Davatzikos; Simon Lovestone; Susan M Resnick
Journal:  Neuroimage       Date:  2011-07-28       Impact factor: 6.556

Review 4.  Clusterin in Alzheimer's disease: a player in the biological behavior of amyloid-beta.

Authors:  Xiang Li; Yifei Ma; Xu Wei; Yanpeng Li; Huijuan Wu; Jianhua Zhuang; Zhongxin Zhao
Journal:  Neurosci Bull       Date:  2013-12-19       Impact factor: 5.203

5.  Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Authors:  David A Elliott; Cyndi Shannon Weickert; Brett Garner
Journal:  Clin Lipidol       Date:  2010-08-01

6.  Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells.

Authors:  O Cordero-Llana; S A Scott; S L Maslen; J M Anderson; J Boyle; R-R Chowhdury; P Tyers; R A Barker; C M Kelly; A E Rosser; E Stephens; S Chandran; M A Caldwell
Journal:  Cell Death Differ       Date:  2011-01-07       Impact factor: 15.828

7.  Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain.

Authors:  M D Martin-Rehrmann; H-S Hoe; E M Capuani; G W Rebeck
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

8.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

9.  Expression of the protein chaperone, clusterin, in spinal cord cells constitutively and following cellular stress, and upregulation by treatment with Hsp90 inhibitor.

Authors:  Samantha Zinkie; Benoit J Gentil; Sandra Minotti; Heather D Durham
Journal:  Cell Stress Chaperones       Date:  2013-04-19       Impact factor: 3.667

10.  Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease.

Authors:  Gustavo Basurto-Islas; Jose Luna-Muñoz; Angela L Guillozet-Bongaarts; Lester I Binder; Raul Mena; Francisco García-Sierra
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.